Clinical Trials Information System (CTIS): Information day, Online, 13:30- 17:30 Amsterdam time (CET), from 17/10/2023 to 17/10/2023

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, COVID-19 virus infection, Date of authorisation: 17/12/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Farydak, panobinostat, Multiple Myeloma, Date of authorisation: 28/08/2015, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, HIV Infections, Date of authorisation: 17/12/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy , semaglutide, Obesity;Overweight, Date of authorisation: 06/01/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Lacosamide Adroiq, lacosamide, Epilepsy, Date of authorisation: 31/05/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Plenadren, hydrocortisone, Adrenal Insufficiency, Date of authorisation: 03/11/2011, Revision: 14, Status: Authorised

Guideline on the calculation of dose factor to be submitted to the Union Product Database (UPD)

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Neuromuscular Blockade, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): levonorgestrel, decision type: , therapeutic area: , PIP number: P/0447/2022